124 related articles for article (PubMed ID: 11488519)
1. Pharmacological study of paclitaxel duration of infusion combined with GFR-based carboplatin in the treatment of ovarian cancer.
Boddy AV; Griffin MJ; Sludden J; Thomas HD; Fishwick K; Wright JG; Plumner ER; Highley M; Calvert AH
Cancer Chemother Pharmacol; 2001 Jul; 48(1):15-21. PubMed ID: 11488519
[TBL] [Abstract][Full Text] [Related]
2. Phase I and pharmacologic study of the combination paclitaxel and carboplatin as first-line chemotherapy in stage III and IV ovarian cancer.
Huizing MT; van Warmerdam LJ; Rosing H; Schaefers MC; Lai A; Helmerhorst TJ; Veenhof CH; Birkhofer MJ; Rodenhuis S; Beijnen JH; ten Bokkel Huinink WW
J Clin Oncol; 1997 May; 15(5):1953-64. PubMed ID: 9164207
[TBL] [Abstract][Full Text] [Related]
3. A phase I study evaluating the safety and pharmacokinetics of weekly paclitaxel and carboplatin in relapsed ovarian cancer.
Leiser AL; Maluf FC; Chi DS; Sabbatini P; Hensley ML; Schwartz L; Venkatraman E; Spriggs D; Aghajanian C
Int J Gynecol Cancer; 2007; 17(2):379-86. PubMed ID: 17362316
[TBL] [Abstract][Full Text] [Related]
4. Paclitaxel and carboplatin combination chemotherapy in a hemodialysis patient with advanced ovarian cancer.
Watanabe M; Aoki Y; Tomita M; Sato T; Takaki Y; Kato N; Kikuchi M; Kase H; Tanaka K
Gynecol Oncol; 2002 Feb; 84(2):335-8. PubMed ID: 11812097
[TBL] [Abstract][Full Text] [Related]
5. A pilot study of paclitaxel and carboplatin for recurrent ovarian cancer.
Adachi S; Ogasawara T; Ito K; Koyama M; Nagano T; Suzuki A; Yamada T; Nakata Y; Ozawa M
Oncol Rep; 2001; 8(2):285-8. PubMed ID: 11182041
[TBL] [Abstract][Full Text] [Related]
6. Clinical pharmacology of carboplatin administered in combination with paclitaxel.
van Warmerdam LJ; Huizing MT; Giaccone G; Postmus PE; ten Bokkel Huinink WW; van Zandwijk N; Koolen MG; Helmerhorst TJ; van der Vijgh WJ; Veenhof CH; Beijnen JH
Semin Oncol; 1997 Feb; 24(1 Suppl 2):S2-97-S2-104. PubMed ID: 9045347
[TBL] [Abstract][Full Text] [Related]
7. Clinical trial and pharmacokinetic study of combination paclitaxel and carboplatin in patients with epithelial ovarian cancer.
Yamamoto R; Kaneuchi M; Nishiya M; Todo Y; Takeda M; Okamoto K; Negishi H; Sakuragi N; Fujimoto S; Hirano T
Cancer Chemother Pharmacol; 2002 Aug; 50(2):137-42. PubMed ID: 12172979
[TBL] [Abstract][Full Text] [Related]
8. Phase I trial, including pharmacokinetic and pharmacodynamic correlations, of combination paclitaxel and carboplatin in patients with metastatic non-small-cell lung cancer.
Belani CP; Kearns CM; Zuhowski EG; Erkmen K; Hiponia D; Zacharski D; Engstrom C; Ramanathan RK; Capozzoli MJ; Aisner J; Egorin MJ
J Clin Oncol; 1999 Feb; 17(2):676-84. PubMed ID: 10080614
[TBL] [Abstract][Full Text] [Related]
9. A clinical and pharmacokinetic study of the combination of carboplatin and paclitaxel for epithelial ovarian cancer.
Siddiqui N; Boddy AV; Thomas HD; Bailey NP; Robson L; Lind MJ; Calvert AH
Br J Cancer; 1997; 75(2):287-94. PubMed ID: 9010040
[TBL] [Abstract][Full Text] [Related]
10. Paclitaxel combined with carboplatin in the first-line treatment of advanced ovarian cancer: a phase I trial.
Meerpohl HG; du Bois A; Luck HJ; Kühnle H; Möbus V; Kreienberg R; Bauknecht T; Köchli O; Bochtler H; Diergarten K
Semin Oncol; 1997 Feb; 24(1 Suppl 2):S2-17-S2-22. PubMed ID: 9045330
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of paclitaxel and carboplatin in combination.
Kearns CM; Belani CP; Erkmen K; Zuhowski M; Hiponia D; Zacharski D; Engstrom C; Ramanathan R; Trenn MR; Aisner J
Semin Oncol; 1995 Oct; 22(5 Suppl 12):1-4; discussion 5-7. PubMed ID: 7481850
[TBL] [Abstract][Full Text] [Related]
12. Carboplatin plus paclitaxel as first-line chemotherapy in previously untreated advanced ovarian cancer. German AGO Study Group Ovarian Cancer. Arbeitsgemeinschaft Gynäkologische Onkologie.
du Bois A; Lück HJ; Meier W; Möbus V; Costa S; Richter B; Bauknecht T; Warm M; Schroeder W; Olbricht S; Nitz U; Jackisch C
Semin Oncol; 1997 Aug; 24(4 Suppl 11):S11-28-S11-33. PubMed ID: 9314296
[TBL] [Abstract][Full Text] [Related]
13. Paclitaxel combined with carboplatin in the first-line treatment of advanced ovarian cancer.
Meerpohl HG; du Bois A; Kühnle H; Lück HJ; Kreienberg R; Möbus V; Bauknecht T; Köchli O; Bochtler H; Diergarten K
Semin Oncol; 1995 Dec; 22(6 Suppl 15):7-12. PubMed ID: 8643973
[TBL] [Abstract][Full Text] [Related]
14. A phase I and pharmacokinetic study of weekly paclitaxel and carboplatin in patients with metastatic esophageal cancer.
Polee MB; Sparreboom A; Eskens FA; Hoekstra R; van de Schaaf J; Verweij J; Stoter G; van der Gaast A
Clin Cancer Res; 2004 Mar; 10(6):1928-34. PubMed ID: 15041708
[TBL] [Abstract][Full Text] [Related]
15. A clinical and pharmacokinetic study of high-dose carboplatin, paclitaxel, granulocyte colony-stimulating factor, and peripheral blood stem cells in patients with unresectable or metastatic cancer.
Shea T; Graham M; Bernard S; Steagall A; Wiley J; Serody J; Brecher M; Bentley S; Johnston C; Vaisman A
Semin Oncol; 1995 Oct; 22(5 Suppl 12):80-5. PubMed ID: 7481867
[TBL] [Abstract][Full Text] [Related]
16. Carboplatin and paclitaxel in ovarian carcinoma: a phase I study of the Gynecologic Oncology Group.
Bookman MA; McGuire WP; Kilpatrick D; Keenan E; Hogan WM; Johnson SW; O'Dwyer P; Rowinsky E; Gallion HH; Ozols RF
J Clin Oncol; 1996 Jun; 14(6):1895-902. PubMed ID: 8656258
[TBL] [Abstract][Full Text] [Related]
17. Intraperitoneal carboplatin infusion may be a pharmacologically more reasonable route than intravenous administration as a systemic chemotherapy. A comparative pharmacokinetic analysis of platinum using a new mathematical model after intraperitoneal vs. intravenous infusion of carboplatin--a Sankai Gynecology Study Group (SGSG) study.
Miyagi Y; Fujiwara K; Kigawa J; Itamochi H; Nagao S; Aotani E; Terakawa N; Kohno I;
Gynecol Oncol; 2005 Dec; 99(3):591-6. PubMed ID: 16095677
[TBL] [Abstract][Full Text] [Related]
18. Paclitaxel (1-hour) and carboplatin (area under the concentration-time curve 7.5) in advanced non-small cell lung cancer: a phase II study of the Fox Chase Cancer Center and its network.
Langer CJ; Millenson M; Rosvold E; Litwin S; McAleer CA; Bonjo CA; Ozols R
Semin Oncol; 1997 Aug; 24(4 Suppl 12):S12-81-S12-88. PubMed ID: 9331128
[TBL] [Abstract][Full Text] [Related]
19. Paclitaxel/carboplatin as first-line chemotherapy in advanced ovarian cancer: efficacy and adverse effects with special consideration of peripheral neurotoxicity.
Mayerhofer K; Bodner-Adler B; Bodner K; Leodolter S; Kainz C
Anticancer Res; 2000; 20(5C):4047-50. PubMed ID: 11268499
[TBL] [Abstract][Full Text] [Related]
20. Paclitaxel and carboplatin in metastatic non-small cell lung cancer: preliminary results of a phase I study.
Belani CP; Aisner J; Hiponia D; Ramanathan R
Semin Oncol; 1996 Oct; 23(5 Suppl 12):19-21. PubMed ID: 8941406
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
